

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041278 A1

(51) International Patent Classification⁷: **A61K 31/436**,
31/57, 31/167, 31/137, 31/135, 31/44, 31/18, A61P 11/06

(74) Agent: **TABUSHI, Eiji**; c/o Fujisawa Pharmaceutical
Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome,, Yo-
dogawa-ku, Osaka-shi, Osaka 532-8514 (JP).

(21) International Application Number:

PCT/JP2003/014077

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:

4 November 2003 (04.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2002952559 8 November 2002 (08.11.2002) AU

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **FUJISAWA PHARMACEUTICAL CO., LTD.** [JP/JP]; 4-7,
Doshomachi 3-chome, Chuo-Ku,, Osaka-Shi, OSAKA
541-8514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HIRAYAMA,**
Yoshitaka [JP/JP]; c/o Fujisawa Pharmaceutical Co.,
Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi,
Osaka 541-8514 (JP). **MORISHITA, Yoshihiko** [JP/JP];
c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi
3-chome, Chuo-Ku,, Osaka-Shi, Osaka 541-8514 (JP).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF TACROLIMUS (FK506) DERIVATIVES COMBINED WITH BETA2-AGONISTS FOR THE TREATMENT OF ASTHMA

(57) Abstract: Present invention is relating to a new use of FK506 derivatives and β 2-agonist for manufacturing a medicament for simultaneous, separate or sequential use for treating or preventing acute or chronic asthma.